ConductScience.org, home

Paper21828126

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.

Lee JH and 18 others. Blood, 2011. Cited by 117 papers, by iCite.

Cite this record

ConductScience Library. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Papers, record 21828126. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21828126

Download JSON
Disease
acute myeloid leukemia587 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
PubMed
Journal
Blood
PubMed
Year
2011
PubMed
Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
117
iCite
Relative citation ratio, by iCite
3.03
iCite
Revised in PubMed
2026-05-18
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lee JHJe-Hwan
2Joo YDYoung-Don
3Kim HHawk
4Bae SHSung Hwa
5Kim MKMin Kyoung
6Zang DYDae Young
7Lee JLJung-Lim
8Lee GWGyeong Won
9Lee JHJung-Hee
10Park JHJae-Hoo
11Kim DYDae-Young
12Lee WSWon-Sik
13Ryoo HMHun Mo
14Hyun MSMyung Soo
15Kim HJHyo Jung
16Min YJYoung Joo
17Jang YEYae-Eun
18Lee KHKyoo-Hyung
19Cooperative Study Group A for HematologyGroup

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
DaunorubicinMajor topic
Leukemia, Myeloid, AcuteMajor topic
Adolescent
Adult
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Remission Induction
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00474006High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AMLDerived from the trialYesClinicalTrials.gov
NCT06483906Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.BackgroundClinicalTrials.gov

Download CSV of trials

Cited by61

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.

PMIDTitleJournalYearIn PapersSource
41986965Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial.Cancer Sci2026https://conductscience.org/library/papers/41986965PubMed
41073560Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.Leukemia2026https://conductscience.org/library/papers/41073560PubMed
40481098Early replacement of re-induction therapy following failed intensive induction treatment enhances the therapeutic efficacy of newly diagnosed AML.Sci Rep2025https://conductscience.org/library/papers/40481098PubMed
40147876
Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.
Technol Cancer Res Treat2025https://conductscience.org/library/papers/40147876PubMed
39415901Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced?EJHaem2024https://conductscience.org/library/papers/39415901PubMed
38317981Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (de-novo): A comparative retrospective study.Heliyon2024https://conductscience.org/library/papers/38317981PubMed
38066853Improving long-term outcomes with intensive induction chemotherapy for patients with AML.Hematology Am Soc Hematol Educ Program2023https://conductscience.org/library/papers/38066853PubMed
37274294Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia.Front Oncol2023https://conductscience.org/library/papers/37274294PubMed
36276074Treatment options for acute myeloid leukemia patients aged <60 years.Front Oncol2022https://conductscience.org/library/papers/36276074PubMed
36077703A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges.Cancers (Basel)2022https://conductscience.org/library/papers/36077703PubMed
35937938Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date.Cancer Manag Res2022https://conductscience.org/library/papers/35937938PubMed
35898381Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML).Cureus2022https://conductscience.org/library/papers/35898381PubMed
35847688Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia.EJHaem2020https://conductscience.org/library/papers/35847688PubMed
35734931Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.Haematologica2022https://conductscience.org/library/papers/35734931PubMed
35231903Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.Acta Haematol2022https://conductscience.org/library/papers/35231903PubMed
34596937Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.Pediatr Blood Cancer2021https://conductscience.org/library/papers/34596937PubMed
343505123+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?Curr Oncol Rep2021https://conductscience.org/library/papers/34350512PubMed
34320781Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?Haematologica2021https://conductscience.org/library/papers/34320781PubMed
34031004Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone.Clin Lymphoma Myeloma Leuk2021https://conductscience.org/library/papers/34031004PubMed
33666716Protective effects of curcumin on chemical and drug-induced cardiotoxicity: a review.Naunyn Schmiedebergs Arch Pharmacol2021https://conductscience.org/library/papers/33666716PubMed

See all 61 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
DAUNORUBICINCHEMBL178Derived from the trial1https://conductscience.org/library/drugs/CHEMBL178

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21828126

GET https://conductscience.org/api/papers/v1/21828126/cited_by?page=2